AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease
February 08, 2021 07:00 ET
|
AC Immune SA
LAUSANNE, Switzerland, Feb. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway
January 29, 2021 07:00 ET
|
AC Immune SA
Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors High-affinity antibodies against extracellular components of the inflammasome pathway show...
AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay
December 15, 2020 08:00 ET
|
AC Immune SA
Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital Proprietary SupraAntigenTM platform continues to accelerate...
Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of Directors
November 20, 2020 08:40 ET
|
AC Immune SA
Prof. June is a world authority on immune tolerance and adoptive immunotherapy Appointment reaffirms AC Immune’s scientific leadership in neurodegeneration LAUSANNE, Switzerland, Nov. 20, 2020 ...
Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer
November 18, 2020 07:00 ET
|
AC Immune SA
Prof. Streffer is an established authority on neuroscience and biomarker modalities Appointment reaffirms AC Immune’s scientific leadership in neurodegeneration LAUSANNE, Switzerland, Nov. 18,...
AC Immune Reports Q3 2020 Financial Results and Provides Business Update
November 13, 2020 07:00 ET
|
AC Immune SA
Phase 1 trial completed in Lilly Morphomer™ Tau partnership program with plans to evaluate candidates in Alzheimer’s disease and NeuroOrphan indicationsFirst-in-class TDP-43 therapeutic and diagnostic...
AC Immune to Provide Strategy and Pipeline Update During Jefferies Virtual London Healthcare Conference
November 12, 2020 07:00 ET
|
AC Immune SA
LAUSANNE, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development
November 09, 2020 04:00 ET
|
AC Immune SA
LAUSANNE, Switzerland, Nov. 09, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent
October 09, 2020 08:25 ET
|
AC Immune SA
Grant from the ‘EU Joint Programme – Neurodegenerative Disease Research’ (JPND) provides €1.45M in funding for the program AC Immune’s proprietary Morphomer™ platform continues accelerating...
AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease
September 23, 2020 07:00 ET
|
AC Immune SA
Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study; the primary safety endpoint was met Multiple other...